EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Mucopolysaccharidosis IVA: Current Disease Models and Drawbacks

Andrés Felipe Leal iD, Carlos Javier Alméciga-Díaz iD, Shunji Tomatsu iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms242216148 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Andrés Felipe Leal und 2 weiteren Autor:innen. Beteiligte Einrichtung: Nemours Children's Health, Wilmington, DE 19803, USA. Hauptthemen laut MEDLINE: Mucopolysaccharidosis IV, Chondroitinsulfatases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS, NIH HHS, Pontificia Universidad Javeriana.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mucopolysaccharidosis IVA (MPS IVA) is a rare disorder caused by mutations in the N-acetylgalactosamine-6-sulfate-sulfatase (GALNS) encoding gene. GALNS leads to the lysosomal degradation of the glycosaminoglyccreasans keratan sulfate and chondroitin 6-sulfate. Impaired GALNS enzymes result in skeletal and non-skeletal complications in patients. For years, the MPS IVA pathogenesis and the assessment of promising drugs have been evaluated using in vitro (primarily fibroblasts) and in vivo (mainly mouse) models. Even though value information has been raised from those studies, these models have several limitations. For instance, chondrocytes have been well recognized as primary cells affected in MPS IVA and responsible for displaying bone development impairment in MPS IVA patients; nonetheless, only a few investigations have used those cells to evaluate basic and applied concepts. Likewise, current animal models are extensively represented by mice lacking GALNS expression; however, it is well known that MPS IVA mice do not recapitulate the skeletal dysplasia observed in humans, making some comparisons difficult. This manuscript reviews the current in vitro and in vivo MPS IVA models and their drawbacks.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mucopolysaccharidosis IVChondroitinsulfatasesHumansMiceAnimalsKeratan SulfateChondroitin SulfatesChondrocytesDisease Models, Animal

Stichwörter der Autor:innen

chondrocytesfibroblastsmousemucopolysaccharidosis IVArat

Substanzen

Keratan SulfateChondroitin SulfatesChondroitinsulfatasesGALNS protein, human

Autor:innen und Institutionen

  • Nemours Children's Health, Wilmington, DE 19803, USA.
  • Institute for the Study of Inborn Errors of Metabolism, Faculty of Science, Pontificia Universidad Javeriana, Bogotá 110231, Colombia.
  • Faculty of Arts and Sciences, University of Delaware, Newark, DE 19716, USA.
  • Department of Pediatrics, Graduate School of Medicine, Gifu University, Gifu 501-1193, Japan.
  • Department of Pediatrics, Thomas Jefferson University, Philadelphia, PA 19144, USA.

ORCID-Profile: Andrés Felipe Leal, Carlos Javier Alméciga-Díaz, Shunji Tomatsu

Förderung

  • NICHD NIH HHS
  • NIH HHS
  • Pontificia Universidad Javeriana
  • Ministry of Science, Technology, and Innovation from Colombia
  • National MPS Society
  • Austrian MPS society
  • The Carol Ann Foundation
  • Angelo R. Cali & Mary V. Cali Family Foundation

Zitieren

APA

Leal, A. F., Alméciga-Díaz, C. J., & Tomatsu, S. (2023). Mucopolysaccharidosis IVA: Current Disease Models and Drawbacks. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242216148

Vancouver

Leal AF, Alméciga-Díaz CJ, Tomatsu S. Mucopolysaccharidosis IVA: Current Disease Models and Drawbacks. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242216148

BibTeX
@article{Leal2023,
  author = {Leal, Andrés Felipe and Alméciga-Díaz, Carlos Javier and Tomatsu, Shunji},
  title = {Mucopolysaccharidosis IVA: Current Disease Models and Drawbacks},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms242216148}
}
Kostenlos starten →